AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|AAPL289.36+7.62 (+2.70%) ▲|ABBV251.64-2.67 (-1.05%) ▼|ABT90.74-1.97 (-2.12%) ▼|ACN124.44-0.30 (-0.24%) ▼|ADBE205.02-1.41 (-0.68%) ▼|AMAT723.00+28.36 (+4.08%) ▲|AMD580.91+41.42 (+7.68%) ▲|AMGN362.12+1.57 (+0.44%) ▲|AMT163.57-5.10 (-3.02%) ▼|AMZN238.34-1.80 (-0.75%) ▼|AVGO377.75+5.30 (+1.42%) ▲|AXP338.25-2.63 (-0.77%) ▼|BA216.47+1.78 (+0.83%) ▲|BAC56.98-0.90 (-1.55%) ▼|BKNG178.24-4.17 (-2.29%) ▼|BLK961.56+11.39 (+1.20%) ▲|BMY57.62-0.94 (-1.61%) ▼|BNY144.61+0.81 (+0.56%) ▲|BRK-B500.39+4.39 (+0.89%) ▲|C139.96-2.53 (-1.78%) ▼|CAT1,064.90+31.71 (+3.07%) ▲|CL91.68-0.72 (-0.78%) ▼|CMCSA24.55+0.33 (+1.36%) ▲|COF200.62-1.66 (-0.82%) ▼|COP103.96-0.24 (-0.23%) ▼|COST935.47-11.21 (-1.18%) ▼|CRM156.66-1.27 (-0.80%) ▼|CSCO117.46-0.24 (-0.20%) ▼|CVS103.45-0.13 (-0.13%) ▼|CVX165.76-2.71 (-1.61%) ▼|DE634.33+9.32 (+1.49%) ▲|DHR190.48-2.30 (-1.19%) ▼|DIS96.25-1.63 (-1.67%) ▼|DUK126.58-1.75 (-1.36%) ▼|EMR143.15+0.33 (+0.23%) ▲|FDX313.13-12.27 (-3.77%) ▼|GD354.24+6.17 (+1.77%) ▲|GE373.73+0.02 (+0.01%) ▲|GEV1,174.86+72.35 (+6.56%) ▲|GILD126.34+0.01 (+0.01%) ▲|GM77.08-0.26 (-0.34%) ▼|GOOG353.33+2.05 (+0.58%) ▲|GOOGL357.37+3.72 (+1.05%) ▲|GS1,011.37-8.84 (-0.87%) ▼|HD352.68+1.87 (+0.53%) ▲|HON223.90-3.90 (-1.71%) ▼|IBM281.21+3.21 (+1.15%) ▲|INTC139.63+7.91 (+6.01%) ▲|INTU261.00-5.40 (-2.03%) ▼|ISRG397.68-8.29 (-2.04%) ▼|JNJ253.97-4.54 (-1.76%) ▼|JPM327.33-2.06 (-0.63%) ▼|KO81.27-1.38 (-1.67%) ▼|LIN518.94+7.88 (+1.54%) ▲|LLY1,199.43-30.50 (-2.48%) ▼|LMT509.46+7.39 (+1.47%) ▲|LOW220.49+0.84 (+0.38%) ▲|LRCX433.33+22.42 (+5.46%) ▲|MA513.60+3.96 (+0.78%) ▲|MCD270.31+3.13 (+1.17%) ▲|MDLZ57.84-2.31 (-3.84%) ▼|MDT78.23-2.70 (-3.34%) ▼|META563.29+0.69 (+0.12%) ▲|MMM161.91-0.52 (-0.32%) ▼|MO71.95-2.10 (-2.84%) ▼|MRK128.50-0.88 (-0.68%) ▼|MS209.04-2.68 (-1.27%) ▼|MSFT373.02+4.45 (+1.21%) ▲|MU1,154.29+9.01 (+0.79%) ▲|NEE87.77-0.89 (-1.00%) ▼|NFLX71.40-2.38 (-3.23%) ▼|NKE41.05-0.43 (-1.04%) ▼|NOW99.28-0.69 (-0.69%) ▼|NVDA200.09+5.12 (+2.63%) ▲|ORCL146.55-1.21 (-0.82%) ▼|PEP135.40-3.28 (-2.37%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG146.64-1.81 (-1.22%) ▼|PLTR116.67+0.97 (+0.84%) ▲|PM180.91-1.96 (-1.07%) ▼|QCOM184.79-3.93 (-2.08%) ▼|RTX189.73+2.40 (+1.28%) ▲|SBUX102.19-1.87 (-1.80%) ▼|SCHW92.27+1.72 (+1.90%) ▲|SO95.71-1.04 (-1.07%) ▼|SPG223.65-3.91 (-1.72%) ▼|T20.70-1.12 (-5.13%) ▼|TMO501.36-5.06 (-1.00%) ▼|TMUS167.73-6.24 (-3.59%) ▼|TSLA420.60+8.76 (+2.13%) ▲|TXN298.07+12.59 (+4.41%) ▲|UBER72.16-3.34 (-4.42%) ▼|UNH415.63-4.19 (-1.00%) ▼|UNP272.00-0.70 (-0.26%) ▼|UPS107.50-0.51 (-0.47%) ▼|USB60.40-0.36 (-0.59%) ▼|V343.09+1.44 (+0.42%) ▲|VZ42.34-1.76 (-3.99%) ▼|WFC82.64-0.87 (-1.04%) ▼|WMT113.26-1.34 (-1.17%) ▼|XOM136.72+0.66 (+0.49%) ▲|
27.5 C
New York
Wednesday, July 1, 2026

Tag: study

newssourceFORcompanyinformationcontent1releasesmarket

Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025

LUND, Sweden, June 9, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that it will host a virtual investor event...

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including...

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™...

MoneyHero Group Expands Digital Asset Wealth Product Offerings in Hong Kong in Strategic Collaboration with OSL

The collaboration with OSL, a leading regulated platform in Asia, marks MoneyHero's strategic expansion into the digital asset landscape, empowering users to make smarter and more informed financial decisions 
The collaboration with OSL, a leading regulated platform in Asia, marks MoneyHero's strategic expansion into the digital asset landscape, empowering users to make smarter and more informed financial decisions

MoneyHero與OSL達成戰略合作，拓展香港數字資產財富產品服務

攜手亞洲領先持牌平台OSL，MoneyHero戰略佈局數字資產生態，賦能用户做出更明智的財務決策 
攜手亞洲領先持牌平台OSL，MoneyHero戰略佈局數字資產生態，賦能用户做出更明智的財務決策

Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)

HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small...

Elliott Calls for Further Action to Enhance Corporate Value and Strengthen Corporate Governance Ahead of Sumitomo Realty’s 2025 Annual General Meeting

Elliott plans to vote against members of Sumitomo Realty's senior management at the 2025 AGM absent further corporate-governance and value-enhancement initiatives LONDON, June 9, 2025 /PRNewswire/...

‘Study in Beijing’ Thematic Education Exhibition Held in Mexico and Brazil

BEIJING, June 7, 2025 /PRNewswire/ -- A news report from CRI Online: From June 5 to June 12, 2025, the "Study in Beijing" Thematic Education Exhibition was...

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating...

UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman

URGN Investors with Losses Encouraged to Contact Hagens Berman 
URGN Investors with Losses Encouraged to Contact Hagens Berman

Analyzing Silicon Valley’s Fascination with Hobbits—Strategic Implications for Investors

In the realm of disciplined financial strategy and portfolio management, understanding the broader cultural narratives that influence market leaders is as crucial as analyzing...

Jewelry Design Emerges as New Venture Amid Covid Lockdowns—Evaluating Financial Viability

In the wake of the Covid-19 pandemic, many individuals have pivoted towards their passions, resulting in significant impacts on various industries, including the jewelry...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStudy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers